openPR Logo
Press release

Angioedema Treatment Market Revenue Opportunies By Key Vendors Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals

09-26-2018 05:49 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Angioedema-Treatment-Industry

Angioedema-Treatment-Industry

Angioedema is the medical condition characterized by swelling of the lower layer of skin and tissue just under the skin or mucous membrane occurs. There are four main type of angioedema namely allergic angioedema, drug-induced angioedema, Idiopathic angioedema, and hereditary angioedema (HAE). Angioedema is caused by various factors and in most of the cases exact cause is unknown. Major cause of angioedema are allergic reaction, adverse effect of any medication, genetic defects, and infections.
Frequent approval of novel drugs from regulatory bodies is expected to boost growth of global angioedema treatment market.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1371

In 2017, U.S. Food and Drug Administration approved Haegarda, a C1 Esterase Inhibitor (Human) for subcutaneous administration indicated for the preventing hereditary angioedema (HAE) in adult and adolescent patients. In 2014, Pharming Group NV and Salix Pharmaceuticals, Ltd. received US Food and Drug Administration (FDA) approval for RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, indicated for the treatment of acute angioedema attacks in adult and adolescent patients with HAE. In 2016, CSL Behring received FDA approval for Berinert [C1 Esterase Inhibitor (Human)], indicated for the treatment of HAE attacks in pediatric patients. These multiple approvals of new drugs by regulatory bodies are expected to drive growth of global angioedema treatment market over the forecast period. Furthermore, initiatives taken by various organizations to support treatment of angioedema is also expected to support the growth of global angioedema treatment market. For instance in 2015, British Society for Allergy and Clinical Immunology (BSACI) provided a guideline for the management of chronic urticaria and angioedema. In 2013, the World Allergy Organization (WAO) also provided guideline for the Management of Hereditary Angioedema.

Competitive Landscape of Angioedema Treatment Market:
Key players in angioedema treatment market include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency.

Europe angioedema treatment market is expected show significant growth, owing to increasing presence of angioedema drug manufacturers.

Request for Customization of Research Report:
https://www.coherentmarketinsights.com/insight/request-customization/1371

Angioedema Treatment Market Taxonomy:

The angioedema treatment market is segmented on the basis of condition type, drug type, route of administration, distribution channel, and geography

By Condition Type:
• Allergic angioedema
• Drug-induced angioedema
• Idiopathic angioedema
• Hereditary angioedema (HAE)
By Drug Type:
• C1 esterase inhibitor
• Cinryze
• Berinert
• Ruconest
• Haegarda
• Selective bradykinin B2 receptor antagonist
• Firazyr
• Kallikrein inhibitor
• Kalbitor
• Others
By Route of Administration:
• Injection
• Intravenous
• Subcutaneous
• Oral
By Distribution Channel
• Hospitals
• Retail pharmacies
• Online pharmacies

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angioedema Treatment Market Revenue Opportunies By Key Vendors Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals here

News-ID: 1265180 • Views: 534

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Angioedema

Hereditary Angioedema Therapeutics Market - Forecast to 2026
As per the research conducted by GME, the Global Hereditary Angioedema Therapeutics Market will grow with a CAGR value of 8.2%. Population growth, as well as lifestyle changes, improved insurance programs, and increased efforts by pharmaceutical and biotechnology companies to develop new products and solutions for the industry, are expected to fuel market revenue for Hereditary Angioedema in the years ahead. Browse 153 Market Data Tables and 113 Figures spread through
Angioedema Market: Rampant Allergies to Bolster Angioedema Treatment
Angioedema, an edema of spots beneath the skin or mucosa aggravating throat, face, limbs and genitals has taken the lives of more than five thousand people between 1979 and 2010. Unlike urticarial that attacks merely the upper dermis, angioedema strikes the deeper layers, including the dermis, the mucosa, submucosal tissues and the subcutaneous tissue. These assimilations are according to the report titled “Angioedema Market,” which has been recently added to
Angioedema Market: Rampant Allergies to Bolster Angioedema Treatment
Angioedema, an edema of spots beneath the skin or mucosa aggravating throat, face, limbs and genitals has taken the lives of more than five thousand people between 1979 and 2010. Unlike urticarial that attacks merely the upper dermis, angioedema strikes the deeper layers, including the dermis, the mucosa, submucosal tissues and the subcutaneous tissue. These assimilations are according to the report titled “Angioedema Market,” which has been recently added to
Angioedema Treatment Market - Global Industry Analysis 2025
Angioedema is the medical condition characterized by swelling of the lower layer of skin and tissue just under the skin or mucous membrane occurs. There are four main type of angioedema namely allergic angioedema, drug-induced angioedema, Idiopathic angioedema, and hereditary angioedema (HAE). Angioedema is caused by various factors and in most of the cases exact cause is unknown. Major cause of angioedema are allergic reaction, adverse effect of any medication,
Hereditary Angioedema Market Analysis & Key Trends 2025
As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016. Progress in Diagnosis Catalyzing Growth in Market Hereditary angioedema is a rare disease that is estimated to affect 1 in 30,000 to 1 in 50,000 people worldwide. Hereditary angioedema is often mistaken for common
Hereditary Angioedema Market : Global Forecast over 2025
As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016. Superior Healthcare Facilities Makes North America Market Leader Depending upon the class of drugs, the global hereditary angioedema market can be segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor,